Sequana Medical Boosts Share Capital and Share Count
Sequana Medical NV is excited to announce a significant update regarding its share capital and the total number of shares outstanding. As a leading innovator in treating drug-resistant fluid overload caused by liver disease, heart failure, and cancer, the company is committed to improving patients' lives through groundbreaking solutions.
Details of the Capital Increase
Recently, the company experienced a growth in its share capital from EUR 5,535,546.75 to EUR 5,664,269.96. This increase comes after the conversion of certain receivables associated with a convertible loan agreement. The number of outstanding shares has also surged, rising from 53,428,572 to 54,671,074 ordinary shares. This surge entailed the issuance of 1,242,502 new shares, reflecting the company's robust strategy to nourish its growth initiatives.
Outstanding Subscription Rights
Currently, there are 3,899,576 existing subscription rights. Holders of these rights can potentially subscribe to a total of 5,066,304 new shares with voting privileges. This facilitates an excellent opportunity for current stakeholders to engage in the company's future.
Breakdown of Share Options
The breakdown of the outstanding subscription rights is as follows:
- **Executive Share Options:** Up to 261,895 new shares may be issued following exercise of 90,780 share options available under the Executive Share Options plan.
- **2018 Share Options:** A total of 687,784 new shares can emerge from the exercise of the equivalent number of share options under the 2018 plan.
- **2021 Share Options:** This plan offers the possibility of issuing 188,370 new shares through the same number of share options.
- **2023 Share Options:** Holders might benefit from the issuance of 1,000,000 new shares upon exercising those options.
- **Bootstrap Warrants:** Furthermore, Bootstrap Europe S.C.SP is entitled to 302,804 new shares based on 10 outstanding warrants.
- **Kreos Warrants:** Up to 1,567,819 new shares can be subscribed through 875,000 outstanding warrants with Kreos Capital VII Aggregator SCSp.
- **2023 Investor Warrants:** Up to 1,057,632 new shares can be issued for the exercise of the 1,057,632 subscription rights outstanding.
Understanding Sequana Medical's Innovations
Sequana Medical has positioned itself as a trailblazer in addressing fluid overload issues faced by patients with chronic medical conditions. These patients often experience debilitating symptoms that severely impact their quality of life. Traditional diuretic treatments can be only partially effective and might lead to intolerable side effects or worsening conditions. Thus, Sequana Medical aims to deliver innovative therapies to enhance patient outcomes.
The alfa pump® and DSR® Systems
At the core of Sequana Medical's offerings are the **alfa pump®** and **DSR®**. These proprietary technologies facilitate the management of fluid overload efficiently, providing patients significant relief. With the FDA's approval of the alfa pump® system's use for ascites treatment recently secured, Sequana Medical anticipates launching its products in the US market shortly. This forthcoming commercial entry is a landmark moment for the company, allowing them to reach a broader patient demographic.
Future Prospects
As Sequana Medical continues to innovate, recent studies have underscored the efficacy of the DSR® therapy in tackling heart failure challenges. Preliminary outcomes have demonstrated promising enhancements in patients' diuretic response rates, marking an exciting development in cardiac care.
Sequana Medical, listed on the regulated Euronext Brussels market under the ticker SEQUA.BR, is headquartered in Ghent, Belgium. The company is dedicated to advancing its therapies, paving the way for new standards in care.
Frequently Asked Questions
What is the recent share capital increase for Sequana Medical?
Sequana Medical has increased its share capital from EUR 5,535,546.75 to EUR 5,664,269.96, reflecting its growth and innovative strategies.
How many shares are currently issued by Sequana Medical?
The number of outstanding shares has risen to 54,671,074 ordinary shares.
What are the notable therapy options offered by Sequana Medical?
Sequana Medical's key treatments include the alfa pump® and DSR®, which manage fluid overload in patients with serious medical conditions.
What is the potential of subscription rights for current investors?
There are significant subscription rights in place that could allow investors to subscribe to 5,066,304 new shares, providing a great opportunity for engagement.
When does Sequana Medical anticipate launching in the US market?
The company aims to start US commercialization of its products by Q3 2025, tapping into the need for innovative therapies in liver transplant centers.
